 |
0 Diseases |  |
2 Trials |
|
2 Trials |  |
96 News |  |
| 12» |
- masupirdine (SUVN-502) / Suven Life Sci
Masupirdine (a pure 5-HT6 receptor antagonist) for the treatment of agitation in patients with dementia of Alzheimer (WCC Halls A-C) - Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_12061;
P2a, P3
Subject enrolment is expected to be completed by Q3 2024. Phase-3 study data readout is anticipated in Q1/Q2 2025.
- masupirdine (SUVN-502) / Suven Life Sci
Masupirdine (SUVN-502), a pure 5-HT6 receptor antagonist: Rationale for evaluation in patients with agitation in dementia of Alzheimer's type (WCC Halls A-C) - Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_7246;
P2a, P3
In addition, masupirdine significantly modulated levels of dopamine and norepinephrine in brain at a dose of 10 mg/kg, s.c. The post hoc analysis of the Phase-2 study (NCT02580305) in patients with moderate AD suggested treatment with masupirdine at 50 mg and 100 mg significantly decreased the agitation/aggression score from Week 13 to Week 26 suggesting potential treatment effects of masupirdine on agitation/aggression symptoms. To explore the beneficial effects, masupirdine is currently being evaluated as a monotherapy in a global Phase-3 study for the potential treatment of agitation in participants with dementia of Alzheimer's type (NCT05397639).
- masupirdine (SUVN-502) / Suven Life Sci
Masupirdine (SUVN-502) for the Potential Treatment of Agitation in Patients with Dementia of the Alzheimer (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_7307;
P2a, P3
The need for new treatments for the management of agitation is significant and unmet. The Phase-3 study results will inform the utility of masupirdine for the potential treatment of agitation in patients with dementia of Alzheimer
- masupirdine (SUVN-502) / Suven Life Sci
Masupirdine (SUVN-502) for the Potential Treatment of Agitation in Patients with Dementia of the Alzheimer (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_5241;
P2a, P3
The need for new treatments for the management of agitation is significant and unmet. The Phase-3 study results will inform the utility of masupirdine for the potential treatment of agitation in patients with dementia of Alzheimer
- masupirdine (SUVN-502) / Suven Life Sci
Masupirdine (SUVN-502) for the Potential Treatment of Agitation in Patients with Dementia of the Alzheimer (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_2995;
P2a, P3
The need for new treatments for the management of agitation is significant and unmet. The Phase-3 study results will inform the utility of masupirdine for the potential treatment of agitation in patients with dementia of Alzheimer
- masupirdine (SUVN-502) / Suven Life Sci
Masupirdine (SUVN-502) for the Potential Treatment of Agitation in Patients with Dementia of the Alzheimer (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_775;
P2a, P3
The need for new treatments for the management of agitation is significant and unmet. The Phase-3 study results will inform the utility of masupirdine for the potential treatment of agitation in patients with dementia of Alzheimer
- | masupirdine (SUVN-502) / Suven Life Sci, Rexulti (brexpiprazole) / Lundbeck, Otsuka
Journal: A 2023 update on the advancements in the treatment of agitation in Alzheimer's disease. (Pubmed Central) - Mar 25, 2023
Clinical trials remain underway utilizing both novel and repurposed agents to address symptoms of agitation in AD. With increasing understanding of the neurobiological mechanisms that fuel the development of agitation in AD, the use of enhanced trial design and conduct, advanced statistical approaches, and accelerated pathways for regulatory approval, we are advancing closer to having safe and efficacious treatment options for agitation in AD.
- masupirdine (SUVN-502) / Suven Life Sci
Masupirdine (SUVN-502): A Pure 5-HT6 Receptor Antagonist for the Treatment of Agitation/Aggression and Psychosis (SDCC Halls B-H) - Oct 10, 2022 - Abstract #Neuroscience2022NEUROSCIENCE_12371;
P2a, P3
Further exploration is warranted to confirm the beneficial effects of masupirdine in AD patients. Masupirdine is currently being evaluated as a monotherapy in a Phase-3 study for the potential treatment of agitation in participants with dementia of Alzheimer’s type (NCT05397639).
- | masupirdine (SUVN-502) / Suven Life Sci
Retrospective data, Journal: Potential beneficial effects of masupirdine (SUVN-502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses. (Pubmed Central) - Oct 5, 2022
Masupirdine is currently being evaluated as a monotherapy in a Phase-3 study for the potential treatment of agitation in participants with dementia of Alzheimer’s type (NCT05397639). Further research is warranted to explore the potential beneficial effects of masupirdine on NPS.
- masupirdine (SUVN-502) / Suven Life Sci
Phase-3 Study of Masupirdine (SUVN-502), a 5-HT6 Receptor Antagonist, For the Potential Treatment of Agitation in Participants with Dementia of Alzheimer’s Type () - Oct 5, 2022 - Abstract #CTAD2022CTAD_172;
- ||||| masupirdine (SUVN-502) / Suven Life Sci
Trial initiation date: Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type (clinicaltrials.gov) - Aug 31, 2022
P3, N=375, Recruiting, Sponsor: Suven Life Sciences Limited
Further research is warranted to explore the potential beneficial effects of masupirdine on NPS. Initiation date: Jun 2022 --> Sep 2022
- || masupirdine (SUVN-502) / Suven Life Sci
P2 data, Retrospective data, Journal: Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study. (Pubmed Central) - Aug 3, 2022
P2a
Although prespecified study endpoints of the phase 2 study were not met, these exploratory post hoc subgroup observations are hypothesis-generating and suggest that the efficacy of masupirdine was adversely affected by concurrent therapy with memantine. Further assessment of masupirdine to determine its potential role as a treatment option for cognitive deficits associated with AD is warranted.
- masupirdine (SUVN-502) / Suven Life Sci
Effects of Masupirdine (SUVN-502) on Agitation/Aggression and Psychosis in Patients with Probable Alzheimer’s Disease: A Post Hoc Analysis () - Jun 24, 2022 - Abstract #AAIC2022AAIC_864;
- masupirdine (SUVN-502) / Suven Life Sci
Effect of Concurrent Use of Memantine on The Efficacy of Masupirdine (SUVN-502): A Post-hoc Analysis of a Phase-2 Randomized Placebo-Controlled Study () - Jun 24, 2022 - Abstract #AAIC2022AAIC_52;
- || masupirdine (SUVN-502) / Suven Life Sci
Clinical, P2 data, Journal: Effect of masupirdine (SUVN-502) on cognition in patients with moderate Alzheimer's disease: A randomized, double-blind, phase 2, proof-of-concept study. (Pubmed Central) - Jun 8, 2022
P2a
Possible reasons for the observed trial results are discussed. Masupirdine was evaluated in moderate Alzheimer's disease patients.First trial in class with background treatment of donepezil and memantine.Masupirdine was generally safe and well tolerated.Possible reasons for the observed trial results are discussed.
- |||||||||| masupirdine (SUVN-502) / Suven Life Sci
New P3 trial: Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type (clinicaltrials.gov) - May 30, 2022
P3, N=375, Recruiting, Sponsor: Suven Life Sciences Limited
- masupirdine (SUVN-502) / Suven Life Sci
MASUPRIDINE, A SEROTONIN RECEPTOR SUB-TYPE 6 ANTAGONIST FOR THE POTENTIAL TREATMENT OF AGITATION IN PATIENTS WITH ALZHEIMER’S TYPE DEMENTIA () - Mar 9, 2022 - Abstract #ADPD2022ADPD_1882;
P2a
Further exploration is warranted to confirm the beneficial effects of masupirdine on agitation. Currently, a phase-3 study to evaluate the effects of masupirdine on agitation in patients with dementia of the Alzheimer's type is in progress.
- masupirdine (SUVN-502) / Suven Life Sci
BENEFICIAL EFFECTS OF MASUPIRDINE (SEROTONIN RECEPTOR SUB-TYPE 6 ANTAGONIST) ON PSYCHOSIS IN PATIENTS WITH ALZHEIMER’S DISEASE () - Mar 9, 2022 - Abstract #ADPD2022ADPD_1355;
P2a
Currently, a phase-3 study to evaluate the effects of masupirdine on agitation in patients with dementia of the Alzheimer's type is in progress. Further exploration is warranted to confirm the beneficial effects of masupirdine on psychosis associated with AD.
- masupirdine (SUVN-502) / Suven Life Sci
Masupirdine (SUVN-502), A Serotonin Receptor Sub-Type 6 Antagonist for the Potential Treatment of Agitation and Psychosis in Patients with Dementia of Alzheimer’s Type ([VIRTUAL]) - Mar 6, 2022 - Abstract #AAN2022AAN_1904;
P2a
Further exploration of masupirdine is warranted to confirm the beneficial effects on agitation and psychosis. Currently, a Phase-3 study evaluating the effect of masupirdine on agitation in patients with dementia of the Alzheimer's type is in progress.
- masupirdine (SUVN-502) / Suven Life Sci
Masupirdine (SUVN-502): A promising clinical candidate for the management of agitation in patients with dementia of Alzheimer’s type (Virtual Only) - Dec 20, 2021 - Abstract #Neuroscience2021Neuroscience_3152;
Masupirdine could be a differentiated therapeutic option for the management of agitation/aggression in Alzheimer's patients. Masupirdine is currently being studied for the management of agitation in patients with dementia of Alzheimer's type.
- masupirdine (SUVN-502) / Suven Life Sci
[VIRTUAL] Beneficial Effects of Masupirdine on Agitation in Patients with Alzheimer’s disease: A Novel Non-sedating Mechanism () - Oct 16, 2021 - Abstract #CTAD2021CTAD_285;
P2a
Further exploration is warranted to confirm the beneficial effects of masupirdine on agitation. Currently, a phase-3 study to evaluate the effects of masupirdine on agitation in patients with dementia of the Alzheimer’s type has been initiated.
- masupirdine (SUVN-502) / Suven Life Sci
[VIRTUAL] Beneficial Effects of Masupirdine on Psychosis in Patients with Alzheimer’s disease, Addressing Limitations of Current Pharmacological Interventions () - Oct 16, 2021 - Abstract #CTAD2021CTAD_274;
P2a
Currently, a phase-3 study to evaluate the effects of masupirdine on agitation in patients with dementia of the Alzheimer’s type has been initiated. Further exploration is warranted to confirm the beneficial effects of masupirdine on psychosis associated with AD.
- masupirdine (SUVN-502) / Suven Life Sci
[VIRTUAL] Masupirdine (SUVN-502): A promising clinical candidate for the management of agitation in Alzheimer’s dementia () - Aug 2, 2021 - Abstract #AAIC2021AAIC_3341;
Masupirdine showed clinically meaningful improvement in the neuropsychiatric symptoms associated with agitation/aggression in patients with AD and reduced aggression in animal models. Masupirdine could be a differentiated novel therapeutic option for the management of agitation/ aggression in Alzheimer’s patients.
- masupirdine (SUVN-502) / Suven Life Sciences, donepezil / Generic mfg.
[VIRTUAL] Masupirdine (SUVN-502): Novel Treatment Option For the Management of Behavioral and Psychological Symptoms in Patients with Alzheimers Disease () - Aug 2, 2020 - Abstract #AAIC2020AAIC_3387;
Masupirdine treatment significantly reduced the behavioral and psychological symptoms i.e., agitation/aggression and psychotic symptoms (delusions and hallucinations) with positive effect on cognition. Masupirdine could be a differentiated novel therapeutic treatment option for the management of behavioral and psychological symptoms in patients with AD.
- masupirdine (SUVN-502) / Suven Life Sciences, Namzaric (memantine ER/donepezil) / Adamas, AbbVie, donepezil / Generic mfg.
[VIRTUAL] Masupirdine in Combination with Donepezil and Memantine in Patients with Moderate Alzheimer's Disease: Subgroup Analyses of Memantine Regimen, Plasma Concentrations and Duration of Treatment () - Aug 2, 2020 - Abstract #AAIC2020AAIC_3378;
Subgroup analyses of the masupirdine Phase 2 POC study to assess potential effects of memantine regimen, memantine plasma concentrations and duration of treatment on primary and secondary study outcomes revealed several potential signals for differential effects favoring masupirdine treatment. These observations merit better understanding and further possible investigations of masupirdine as a potential treatment for AD dementia.
- masupirdine (SUVN-502) / Suven Life Sciences, Namzaric (memantine ER/donepezil) / Adamas, AbbVie, donepezil / Generic mfg.
[VIRTUAL] Masupirdine (SUVN-502) in Combination with Donepezil and Memantine in Moderate Alzheimer's Disease - Effect of AD Duration Since Diagnosis and Patients Age on Efficacy Endpoints () - Aug 2, 2020 - Abstract #AAIC2020AAIC_3340;
These observations merit better understanding and further possible investigations of masupirdine as a potential treatment for AD dementia. Together with the safety profile of masupirdine, the outcome from these subgroup analyses supports the potential clinical utility of masupirdine in patients with AD.
- masupirdine (SUVN-502) / Suven Life Sciences
[VIRTUAL] Masupirdine (SUVN-502): A Pure 5-HT6 Receptor Antagonist Ameliorates Aggression Like Behavior in Animal models () - Aug 2, 2020 - Abstract #AAIC2020AAIC_1681;
Together with the safety profile of masupirdine, the outcome from these subgroup analyses supports the potential clinical utility of masupirdine in patients with AD. Results from the current preclinical studies indicate the promising therapeutic potential for masupirdine in the treatment of agitation/aggression.
- ||| masupirdine (SUVN-502) / Suven Life Sciences
Preclinical: Live @ #AAIC20 Suven's 5-HT6R antagonist masupirdine shows reduction in aggressive behavior in mice; similar effect seen in humans (Twitter) - Jul 27, 2020
- || masupirdine (SUVN-502) / Suven Life Sciences
@AurobindoO @Alivira2 @AulasGSK @Alkem_Lab @LillyPad @Bioconlimited @ZydusUniverse @NATCOPharmaLtd @drreddys @DaburIndia @EmcurePharma @GranulesIndia @GrasimInd @indswiftgroup @hetero @LupinIndia @JubilantLifeSci @Merck @LaurusLabs @Suvn502 @SunPharma_Live @Pharma_Mankind (Twitter) - Jun 7, 2020
- masupirdine (SUVN-502) / Suven Life Sciences
[VIRTUAL] POTENTIAL BENEFITS OF MASUPIRDINE ON NEUROPSYCHIATRIC SYMPTOMS IN PATIENTS WITH ALZHEIMER'S DISEASE (Hall E) - Feb 22, 2020 - Abstract #AATADPD2020AAT_ADPD_1006;
- masupirdine (SUVN-502) / Suven Life Sciences
[VIRTUAL] POTENTIAL SIGNALS OF BENEFIT FOR MASUPIRDINE ON COGNITION, FUNCTION, AND GLOBAL PROGRESSION IN ALZHEIMER’S DISEASE: EXPLORATORY ANALYSES AND IMPLICATIONS (Hall E) - Feb 22, 2020 - Abstract #AATADPD2020AAT_ADPD_1005;
- masupirdine (SUVN-502) / Suven Life Sciences, donepezil / Generic mfg.
Potential benefits of Masupirdine (SUVN-502) on Behavioral and Psychological symptoms in patients with moderate Alzheimer’s Disease () - Jan 21, 2020 - Abstract #AAN2020AAN_3144;
Compared with placebo, masupirdine treatment improved behavioral symptoms as measured by NPI scores, agitation/aggression and delusions. Masupirdine may have a potential utility in the management of BPSD in AD.
- masupirdine (SUVN-502) / Suven Life Sciences, Namzaric (memantine ER/donepezil) / Adamas, AbbVie, donepezil / Generic mfg.
Masupirdine (SUVN-502), a 5-HT6 receptor antagonist in combination with Donepezil and Memantine in moderate Alzheimer’s patients () - Jan 21, 2020 - Abstract #AAN2020AAN_1952;
Post-hoc and hypothesis-generating observations of interest emerged from the detailed data analyses. These findings support further exploration of the potential of Masupirdine.
- masupirdine (SUVN-502) / Suven Life Sciences, Namzaric (memantine ER/donepezil) / Allergan, Adamas, donepezil / Generic mfg.
[VIRTUAL] PATIENT’S AGE AND ITS EFFECT ON COGNITIVE ENDPOINTS - MASUPIRDINE(SUVN-502), TRIPLE THERAPY WITH DONEPEZIL AND MEMANTINE IN MODERATE AD PATIENTS (EXHIBITION HALL) - Jan 6, 2020 - Abstract #AATADPD2020AAT_ADPD_793;
Results from this exploratory subgroup analysis will be discussed. Conclusions Together with the safety profile of masupirdine, the outcome from this exploratory subgroup analysis supports the clinical utility of masupirdine in patients with AD.
- masupirdine (SUVN-502) / Suven Life Sciences, Namzaric (memantine ER/donepezil) / Allergan, Adamas, donepezil / Generic mfg.
[VIRTUAL] BASELINE ADAS-COG11 SCORES AND EFFECT ON COGNITIVE ENDPOINTS - MASUPIRDINE(SUVN-502), TRIPLE THERAPY WITH DONEPEZIL AND MEMANTINE, PATIENTS WITH MODERATE AD (EXHIBITION HALL) - Jan 6, 2020 - Abstract #AATADPD2020AAT_ADPD_792;
At baseline the median ADAS-Cog11 is 27 and the mean (SD) is 28 (7.92). Conclusions Together with the safety profile of masupirdine, the pre-specified analysis based on median ADAS-Cog11 baseline score of ≤ 27 and > 27 (Median) and other exploratory analysis data, masupridine demonstrates clinical utility in AD patients.
- masupirdine (SUVN-502) / Suven Life Sciences, Namzaric (memantine ER/donepezil) / Allergan, Adamas, donepezil / Generic mfg.
[VIRTUAL] MASUPIRDINE (SUVN-502) IN COMBINATION WITH DONEPEZIL AND MEMANTINE IN MODERATE ALZHEIMER'S DISEASE - EFFECT OF AD DURATION ON EFFICACY ENDPOINTS (EXHIBITION HALL) - Jan 6, 2020 - Abstract #AATADPD2020AAT_ADPD_791;
Conclusions The study has been completed. The impact of the AD duration on clinical function will be presented.
- masupirdine (SUVN-502) / Suven Life Sciences, Namzaric (memantine ER/donepezil) / Allergan, Adamas, donepezil / Generic mfg.
[VIRTUAL] MASUPIRDINE (SUVN-502) IN COMBINATION WITH DONEPEZIL AND MEMANTINE - PATIENTS WITH MODERATE AD - MEMANTINE REGIMEN, CONCENTRATIONS AND TREATMENT DURATION (EXHIBITION HALL) - Jan 6, 2020 - Abstract #AATADPD2020AAT_ADPD_790;
Results In the mITT population, 65.7% of subjects were on donepezil 10 mg+memantine 10 mg BID; 17.9% were on donepezil 10 mg daily+Namenda XR 28 mg daily; and 16.4% were on Namzaric – there is no significant differences in assignment across the three treatment arms. Conclusions The results of these exploratory subgroup analyses to assess potential differential effects of memantine regimen, memantine plasma concentrations and memantine treatment duration on outcome measures in this masupridine triple therapy trial will be presented.
- masupirdine (SUVN-502) / Suven Life Sciences, donepezil / Generic mfg.
[VIRTUAL] MASUPIRDINE (SUVN-502): NOVEL TREATMENT OPTION FOR AGITATION/AGGRESSION IN PATIENTS WITH ALZHEIMER’S DISEASE (EXHIBITION HALL) - Jan 6, 2020 - Abstract #AATADPD2020AAT_ADPD_755;
Conclusions Masupirdine could be a novel therapy for agitation/aggression in patients with AD dementia. Masupirdine addresses majority of the safety concerns associated with the current pharmacological therapies used to treat agitation/aggression in AD.
- masupirdine (SUVN-502) / Suven Life Sciences
[VIRTUAL] SPONSORED SYMPOSIUM 4 -POTENTIAL BENEFITS IN COGNITION AND NEUROPSYCHIATRIC SYMPTOMS IN PATIENTS WITH ALZHEIMER'S DISEASE (Hall E) - Jan 6, 2020 - Abstract #AATADPD2020AAT_ADPD_99;
Masupirdine addresses majority of the safety concerns associated with the current pharmacological therapies used to treat agitation/aggression in AD. SYMPOSIUM IS ORGANISED BY MASUPIRDINE (SUVN-502) - NOT INCLUDED IN MAIN EVENT CME/CPD CREDIT
- |||| masupirdine (SUVN-502) / Suven Life Sci
Trial completion: SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study (clinicaltrials.gov) - Nov 18, 2019
P2a, N=563, Completed, Sponsor: Suven Life Sciences Limited
SYMPOSIUM IS ORGANISED BY MASUPIRDINE (SUVN-502) - NOT INCLUDED IN MAIN EVENT CME/CPD CREDIT Active, not recruiting --> Completed
- masupirdine (SUVN-502) / Suven Life Sciences, Namzaric (memantine ER/donepezil) / Allergan, Adamas, donepezil / Generic mfg.
BASELINE ADAS-COG 11 SCORES AND ITS EFFECT ON COGNITIVE ENDPOINTS - MASUPIRDINE (SUVN-502), TRIPLE THERAPY WITH DONEPEZIL AND MEMANTINE IN PATIENTS WITH MODERATE ALZHEIMER’S DISEASE. () - Oct 20, 2019 - Abstract #CTAD2019CTAD_310;
Together with the safety pro le of masupirdine, the pre-specified analysis based on median ADAS-Cog11 baseline score of ≤ 27 and > 27 (Median) and other exploratory analysis data, masupridine demonstrates clinical utility in AD patients. Results of these exploratory subgroup analyses will be presented at CTAD-2019.
- masupirdine (SUVN-502) / Suven Life Sciences, Namzaric (memantine ER/donepezil) / Allergan, Adamas, donepezil / Generic mfg.
EXPLORATORY SUBGROUP ANALYSES BASED ON PATIENT’S AGE AND ITS EFFECT ON COGNITIVE ENDPOINTS - MASUPIRDINE (SUVN-502), TRIPLE THERAPY WITH DONEPEZIL AND MEMANTINE IN MODERATE ALZHEIMER’S DISEASE PATIENTS. () - Oct 20, 2019 - Abstract #CTAD2019CTAD_309;
Results of these exploratory subgroup analyses will be presented at CTAD-2019. Together with the safety pro le of masupirdine, the outcome from this exploratory subgroup analysis supports the clinical utility of masupirdine in patients with AD.
- masupirdine (SUVN-502) / Suven Life Sciences, Namzaric (memantine ER/donepezil) / Allergan, Adamas, donepezil / Generic mfg.
AD DIAGNOSIS DURATION IN COMBINATION WITH MEMANTINE EXPOSURES ON MASUPIRDINE (SUVN-502) EFFICACY - MASUPIRDINE IN COMBINATION WITH DONEPEZIL AND MEMANTINE IN MODERATE ALZHEIMER’S DISEASE PATIENTS. () - Oct 20, 2019 - Abstract #CTAD2019CTAD_308;
Together with the safety pro le of masupirdine, the outcome from this exploratory subgroup analysis supports the clinical utility of masupirdine in patients with AD. The results from the subgroup analyses evaluating the effect of AD diagnosis duration (> 2 years) in combination with exposures of memantine on masupirdine e cacy will be presented at CTAD-2019.
- masupirdine (SUVN-502) / Suven Life Sciences, Namzaric (memantine ER/donepezil) / Allergan, Adamas, donepezil / Generic mfg.
MASUPIRDINE (SUVN-502), IN COMBINATION WITH DONEPEZIL AND MEMANTINE IN MODERATE ALZHEIMER’S DISEASE - EFFECT OF AD DURATION SINCE DIAGNOSIS ON EFFICACY ENDPOINTS. () - Oct 20, 2019 - Abstract #CTAD2019CTAD_307;
The study has been completed. The impact of the AD duration on clinical function will be presented at CTAD-2019.
- masupirdine (SUVN-502) / Suven Life Sciences, donepezil / Generic mfg.
Potential benefits of Masupirdine (SUVN-502) on behavioral and psychological symptoms in patients with moderate Alzheimer's Disease () - Oct 20, 2019 - Abstract #CTAD2019CTAD_145;
With regard to behavioral symptoms, masupirdine therapy compared with placebo, improved behavioral symptoms as measured by NPI scores, individual domains of agitation/aggression and delusions. Masupirdine may have a potential utility in the management of behavioral and psychotic symptoms in AD.
- masupirdine (SUVN-502) / Suven Life Sciences, Namzaric (memantine ER/donepezil) / Allergan, Adamas, donepezil / Generic mfg.
Masupirdine (SUVN-502) in combination with donepezil and memantine in patients with moderate Alzheimer's disease: Exploratory subgroup analyses of memantine regimen, concentrations and duration of treatment () - Oct 20, 2019 - Abstract #CTAD2019CTAD_144;
Masupirdine is safe and well tolerated. The results of these exploratory subgroup analyses suggests potential di erential e ects of memantine regimen, memantine plasma concentrations and memantine treatment duration on outcome measures of masupridine triple therapy.
- BAN2401 / Biogen, BioArctic Neurosci, Eisai, donepezil / Generic mfg.
PERSISTENCE OF BAN2401-MEDIATED AMYLOID REDUCTIONS POST-TREATMENT: A PRELIMINARY COMPARISON OF AMYLOID STATUS BETWEEN THE CORE PHASE OF BAN2401-G000-201 AND BASELINE OF THE OPEN-LABEL EXTENSION PHASE IN SUBJECTS WITH EARLY ALZHEIMER’S DISEASE () - Oct 16, 2019 - Abstract #CTAD2019CTAD_25;
The current study involving Triple therapy of Masupirdine + Donepezil + Memantine missed its primary and secondary efficacy endpoints. Post-hoc and hypothesis-generating observations of interest emerged from the detailed data analyses.
- masupirdine (SUVN-502) / Suven Life Sciences, donepezil / Generic mfg.
MASUPIRDINE (SUVN-502), A 5-HT6 RECEPTOR ANTAGONIST IN COMBINATION WITH DONEPEZIL AND MEMANTINE IN MODERATE ALZHEIMER’S PATIENTS: STUDY OUTCOMES FROM A PHASE-2 STUDY. () - Oct 16, 2019 - Abstract #CTAD2019CTAD_8;
P=N/A
Our 5-year data con rm the results of the multidomain intervention plus omega 3 in subject who are more likely to decline (APOE ε4 carriers, amyloid-positive and low Red Blood Cell DHA+EPA). Funding: French Ministry of Health, Pierre Fabre Research Institute, Gerontopole, Exhonit Therapeutics SA, Avid Radiopharmaceuticals Inc.
- | masupirdine (SUVN-502) / Suven Life Sci
Trial completion date, Trial primary completion date: SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study (clinicaltrials.gov) - Aug 28, 2019
P2a, N=563, Active, not recruiting, Sponsor: Suven Life Sciences Limited
Funding: French Ministry of Health, Pierre Fabre Research Institute, Gerontopole, Exhonit Therapeutics SA, Avid Radiopharmaceuticals Inc. Trial completion date: May 2019 --> Oct 2019 | Trial primary completion date: Apr 2019 --> Sep 2019
- | masupirdine (SUVN-502) / Suven Life Sciences
Journal: SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, behavioral, and neurochemical characterization. (Pubmed Central) - Aug 8, 2019
The beneficial effects of SUVN-502 on learning and memory might be mediated through the modulation of cholinergic and/or glutamatergic neurotransmission in relevant brain regions. In summary, behavioral, neurochemical, and electrophysiological outcomes indicate that SUVN-502 may augment the beneficial effects of donepezil and memantine combination.